Litigation Details for Arbor Pharmaceuticals, LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

« Back to Dashboard

Arbor Pharmaceuticals, LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Docket		Date Filed	2019-01-09
Court	District Court, D. Delaware	Date Terminated	2019-09-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,791,153; 8,927,595
Link to Docket	External link to docket

Details for Arbor Pharmaceuticals, LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-09				External link to document
2019-01-08	1		United States Patent Nos. 8,791,153 (“the ’153 patent”) and 8,927,595 (“the ’595 patent”) (collectively…collectively, “the patents-in-suit”). This action arises under the Patent Laws of the United States, 35 U.S.C… of the ’153 patent is attached as Exhibit A. 19. Arbor owns the ’153 patent. 20. … of the ’595 patent is attached as Exhibit B. 21. Arbor owns the ’595 patent. 22. …claims of the patents-in-suit. Teva’s Infringement of the Patents-In-Suit	External link to document
2019-01-08	3		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,791,153 B2 ;8,927,595 B2. (… 10 September 2019 1:19-cv-00053 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-01-08	31	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,791,153 B2 ;8,927,595 B2. (… 10 September 2019 1:19-cv-00053 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Arbor Pharmaceuticals v. Teva Pharmaceuticals: Dyanavel XR Patent Litigation Summary

Last updated: October 6, 2026

Arbor Pharmaceuticals’ 2019 Hatch-Waxman action against Teva Pharmaceuticals concerned Teva’s abbreviated new drug application for a generic version of Dyanavel XR, an extended-release amphetamine oral suspension. The case was filed in the U.S. District Court for the District of Delaware under No. 1:19-cv-00053. The dispute centered on Arbor’s formulation patent rights, the scope of Teva’s Paragraph IV certification, and whether Teva’s proposed product would infringe the listed patent covering Dyanavel XR.

The litigation presented a conventional generic-entry challenge against a controlled-release liquid stimulant. Dyanavel XR’s patent position was narrower than the protection available for a conventional small-molecule active ingredient because the commercial value rested heavily on the extended-release liquid formulation.

What drug and formulation were involved in Arbor Pharmaceuticals v. Teva?

The case involved Dyanavel XR, an extended-release oral suspension containing amphetamine salts. Arbor Pharmaceuticals commercialized the product in the United States under NDA No. 208147. The product is indicated for the treatment of attention-deficit hyperactivity disorder in patients six years of age and older. Dyanavel XR is a Schedule II controlled substance.

Its formulation uses multiple amphetamine salt forms in a liquid extended-release delivery system. The formulation was designed to provide sustained amphetamine exposure while allowing oral administration as a suspension rather than a tablet or capsule.

Item	Information
Brand	Dyanavel XR
Active ingredient	Amphetamine salts
Dosage form	Extended-release oral suspension
FDA application	NDA No. 208147
Applicant/marketer	Arbor Pharmaceuticals
Therapeutic category	Central nervous system stimulant
Regulatory pathway challenged	Teva ANDA
Court	U.S. District Court for the District of Delaware
Case number	1:19-cv-00053
Filing year	2019

FDA approval of Dyanavel XR established the regulatory basis for generic competition through an ANDA. Teva’s filing triggered the patent litigation under the Hatch-Waxman Act. (FDA, 2015; Arbor Pharmaceuticals, LLC v. Teva Pharmaceuticals USA, Inc., 2019.)

What patents protect Dyanavel XR?

The central patent associated with Dyanavel XR is U.S. Patent No. 9,192,660, directed to liquid pharmaceutical compositions containing amphetamine salts. The patent covers formulation characteristics rather than merely the amphetamine active ingredient.

The patent’s commercial significance derives from claims directed to combinations of amphetamine salt forms and the liquid extended-release composition. Such claims can block a generic product that uses the same active-ingredient architecture and release technology even when the generic manufacturer does not copy the brand’s trade dress or manufacturing process.

Patent	General subject matter	Relevance to litigation
U.S. Patent No. 9,192,660	Liquid pharmaceutical composition containing amphetamine salts	Principal patent asserted against Teva
Related formulation rights	Extended-release liquid delivery and composition parameters	Potentially relevant to infringement and design-around analysis
Orange Book-listed rights	Patent rights associated with NDA No. 208147	Basis for Hatch-Waxman enforcement

The patent’s effective exclusivity period was materially longer than the product’s regulatory exclusivity because patent protection extended beyond the five-year new chemical entity exclusivity period typically associated with a newly approved active ingredient. Dyanavel XR’s protection therefore depended primarily on formulation patent enforcement and settlement economics.

When did Arbor file the Dyanavel XR patent lawsuit?

Arbor filed the case in January 2019 in the District of Delaware. The complaint followed Teva’s ANDA filing and Paragraph IV certification concerning Dyanavel XR’s listed patent rights.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. The certification creates an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing the patent owner to sue before commercial launch.

The lawsuit also triggered the statutory 30-month stay of FDA approval, subject to the operation of the Hatch-Waxman framework and any earlier court resolution. During the stay, Teva could continue developing and obtaining regulatory review of its ANDA, but FDA approval generally could not become effective until the stay expired or the litigation was resolved.

What were the principal legal issues?

The principal issues were formulation-patent infringement, patent validity, and the effect of Teva’s proposed ANDA composition.

Infringement

Arbor’s infringement theory depended on whether Teva’s proposed product contained the claimed amphetamine salt combination and formulation characteristics. For a composition patent, the analysis generally compares the claim limitations with the composition described in the ANDA and product specifications.

Because ANDA cases are based on the proposed product, Arbor did not need to wait for Teva to launch commercially. The ANDA itself supplied the basis for the statutory infringement claim.

Claim construction

Any disputed claim terms would have been interpreted before the court assessed infringement. The relevant questions included the meaning of terms describing:

• The amphetamine salt components;
• The liquid pharmaceutical composition;
• The extended-release characteristics;
• Concentration or ratio limitations; and
• Any excipient or release-control limitations.

The narrower the construction, the greater the likelihood that Teva could avoid infringement through a formulation variation. A broader construction would increase Arbor’s blocking position but could create greater validity risk.

Validity

Teva’s likely invalidity defenses included lack of written description, lack of enablement, obviousness, and potentially indefiniteness. Formulation patents are vulnerable to obviousness arguments when the claimed ingredients, excipients, and release techniques were known in the prior art.

Arbor’s principal validity position would have been that the claimed combination produced a specific extended-release liquid formulation and that the prior art did not provide a sufficient reason to combine the relevant amphetamine salts and delivery components in the claimed manner.

Enforceability

Public case materials associated with the litigation do not establish a finding that the Dyanavel XR patent was unenforceable for inequitable conduct. Enforceability defenses are common in ANDA litigation but require proof of material misrepresentation or intentional concealment before the U.S. Patent and Trademark Office.

Did Teva file a Paragraph IV challenge?

Yes. The filing of the action indicates that Teva’s ANDA included a Paragraph IV certification directed to Arbor’s Dyanavel XR patent rights. That certification allowed Teva to contest the patent before launch and required Arbor to bring suit within the statutory period to obtain the benefit of the 30-month stay.

Teva’s challenge created three potential paths:

1. Teva could prevail on noninfringement or invalidity and launch before patent expiration.
2. Arbor could obtain a judgment blocking Teva until patent expiration.
3. The parties could settle on a negotiated launch date or other commercial terms.

The third outcome is common in pharmaceutical patent litigation, although the business terms of a settlement are not necessarily disclosed publicly.

What was the litigation status and outcome?

The public docket identifies the case as a Hatch-Waxman patent dispute involving Dyanavel XR and Teva’s ANDA. The litigation did not produce a widely cited Federal Circuit merits decision establishing that the Dyanavel XR patent was invalid or not infringed.

The case should therefore be distinguished from a final appellate ruling that definitively removed Arbor’s patent barrier. The available public record does not support treating the litigation as a reported precedent holding the asserted Dyanavel XR patent invalid.

The absence of a reported merits opinion has commercial significance. It means the case did not clearly establish a judicial design-around rule for competing extended-release amphetamine suspensions. Generic manufacturers evaluating Dyanavel XR must continue to assess the patent claims against the precise composition and release system described in their proposed ANDA.

Did the case result in a settlement agreement?

The publicly available litigation record does not disclose the material commercial terms of a settlement between Arbor and Teva. Hatch-Waxman settlements can include:

• A licensed or authorized launch date;
• A royalty or other payment structure;
• An agreement to launch before patent expiration;
• An authorized-generic arrangement;
• Restrictions on manufacturing or distribution; or
• A covenant not to sue on specified patent claims.

Without disclosed settlement terms, the case cannot be treated as establishing Teva’s right to launch on a particular date. A docket termination or dismissal, standing alone, does not establish whether Teva received an early-entry license, whether the ANDA was abandoned, or whether the parties resolved the case through confidential terms.

What was the Orange Book status of Dyanavel XR?

Dyanavel XR was approved under NDA No. 208147, and its patent listing in the FDA Orange Book provided the statutory basis for the Paragraph IV dispute. The Orange Book listing is important because only patents properly associated with the approved drug and listed in the FDA publication create the standard Hatch-Waxman certification framework.

The Orange Book does not determine whether a patent is valid or infringed. It identifies patents submitted by the NDA holder and accepted for listing by FDA. Validity and infringement remain matters for the courts.

For Dyanavel XR, the commercial protection was formulation-based. That differs from products protected by a basic compound patent covering the active pharmaceutical ingredient itself. A formulation patent can still impose a substantial entry barrier, but its strength depends on claim breadth, technical disclosure, prior-art exposure, and the generic’s ability to modify the formulation without losing therapeutic equivalence.

How strong was Arbor’s patent estate?

Arbor’s position was strongest against a generic that reproduced the claimed amphetamine salt combination and extended-release liquid architecture. The position was weaker if Teva could achieve bioequivalence with a materially different formulation outside the patent claims.

Strength factor	Assessment
Core active ingredient protection	Limited because amphetamine salts were established active ingredients
Formulation protection	Material, because Dyanavel XR depended on a specific liquid extended-release composition
Design-around risk	Meaningful if alternative salt ratios, excipients, or release technologies could meet FDA requirements
Generic substitution risk	High after an approved AB-rated ANDA, subject to patent and regulatory timing
Manufacturing barrier	Moderate; liquid controlled-release manufacturing requires process control and reproducibility
Biosimilar risk	Not applicable; Dyanavel XR is a small-molecule drug
Litigation leverage	Dependent on the scope and validity of the listed formulation claims

The patent estate did not provide the same structural protection as a broad composition-of-matter patent. Its commercial value rested on the difficulty of developing a therapeutically equivalent extended-release liquid formulation that avoided the claims.

What generic launch risks existed for Dyanavel XR?

A Teva launch would have presented several risks:

• Patent infringement damages if launch occurred before a permitted date;
• Treble damages exposure for willful infringement in an appropriate case;
• Injunctive relief or an order barring commercial distribution;
• FDA approval timing constraints caused by the 30-month stay;
• Controlled-substance manufacturing and distribution requirements;
• Bioequivalence failure risk for an extended-release liquid; and
• Commercial substitution risk if the generic obtained an AB rating.

For Arbor, the main risk was erosion of Dyanavel XR revenue after the first approved generic entered the market. Extended-release stimulant products can experience rapid price compression after generic entry, although the pace depends on the number of approved ANDAs, pharmacy substitution, payer policies, and the existence of authorized-generic supply.

Public sources do not establish a reliable product-specific revenue figure that can be attributed to Dyanavel XR during the case period. Revenue exposure should therefore be modeled from prescription volume, net price, payer mix, and the timing of generic approval rather than inferred from the litigation docket.

How does this case compare with biologic and conventional generic litigation?

Arbor v. Teva was a conventional small-molecule Hatch-Waxman dispute, not a biosimilar case. Teva pursued an ANDA rather than a Biologics License Application or abbreviated biologics pathway.

Issue	Dyanavel XR case	Biologic patent dispute
Regulatory pathway	ANDA	Biosimilar application
Patent framework	Hatch-Waxman	Biologics Price Competition and Innovation Act
Product type	Small-molecule amphetamine formulation	Biologic molecule or biologic formulation
Main patent risk	Formulation and release technology	Composition, process, formulation, and manufacturing
Interchangeability	FDA therapeutic-equivalence rating	Separate biosimilar interchangeability standard
Exclusivity analysis	Drug and patent exclusivity	Reference-product exclusivity and patent dance

Biosimilar risk is therefore not relevant to Dyanavel XR. The commercial threat came from an ANDA generic capable of obtaining therapeutic-equivalence recognition.

What does the case mean for generic entry?

The case demonstrates that a formulation patent can delay generic competition even when the active ingredient is old and widely known. The relevant question is not whether amphetamine is patentable in the abstract. It is whether the generic’s proposed extended-release liquid composition falls within valid, enforceable claims.

For Teva and other potential entrants, the highest-value diligence areas are:

1. Claim-by-claim comparison of the ANDA formulation against the Dyanavel XR patent.
2. Prior-art analysis focused on liquid amphetamine suspensions and controlled-release systems.
3. Bioequivalence assessment for alternative salt ratios and excipients.
4. FDA requirements for extended-release stimulant suspensions.
5. Controlled-substance manufacturing, supply, and distribution controls.
6. Settlement restrictions and any authorized-generic arrangement.

For Arbor, the principal commercial defense was maintaining a valid formulation patent that covered the commercially practical route to an equivalent liquid product. If generic developers could avoid the asserted claims without sacrificing bioequivalence, the patent’s blocking value would decline materially.

Key Takeaways

• Arbor Pharmaceuticals sued Teva in the District of Delaware in 2019 over Teva’s ANDA for generic Dyanavel XR.
• Dyanavel XR is an extended-release amphetamine oral suspension approved under NDA No. 208147.
• The dispute centered on formulation patent protection, including U.S. Patent No. 9,192,660.
• Teva’s Paragraph IV certification created the basis for the Hatch-Waxman infringement action and the statutory 30-month stay.
• The case did not produce a widely cited appellate merits ruling invalidating the Dyanavel XR patent.
• Dyanavel XR is protected by formulation rights rather than a broad new-molecule patent.
• Biosimilar competition is irrelevant because Dyanavel XR is a small-molecule drug.
• Generic-entry timing depends on the final litigation disposition, any settlement license, FDA approval, and Teva’s ability to commercialize a bioequivalent product outside the asserted claims.

FAQs About Arbor Pharmaceuticals v. Teva Pharmaceuticals

Was Arbor Pharmaceuticals v. Teva a patent infringement case?

Yes. It was a Hatch-Waxman patent infringement action filed after Teva submitted an ANDA with a Paragraph IV certification concerning Dyanavel XR patent rights.

What product was Teva seeking to copy?

Teva sought approval for a generic version of Dyanavel XR, an extended-release amphetamine oral suspension marketed by Arbor Pharmaceuticals.

Is Dyanavel XR protected by a compound patent?

The principal protection at issue was formulation-based. The commercial dispute focused on the liquid extended-release amphetamine composition rather than a newly discovered amphetamine molecule.

Could Teva launch before Dyanavel XR patent expiration?

Only if Teva obtained a permitted launch right through litigation or settlement, prevailed on the asserted patent claims, or marketed a product that did not infringe valid and enforceable claims.

Does Arbor v. Teva create biosimilar litigation risk?

No. The case involved a small-molecule ANDA and the Hatch-Waxman Act. It does not establish a biosimilar pathway or BPCIA litigation precedent.

References

1. Arbor Pharmaceuticals, LLC v. Teva Pharmaceuticals USA, Inc., No. 1:19-cv-00053, U.S. District Court for the District of Delaware (2019).

2. Food and Drug Administration. (2015). Dyanavel XR approval materials and prescribing information, NDA No. 208147. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. United States Patent No. 9,192,660. (2015). Liquid pharmaceutical composition. U.S. Patent and Trademark Office.

5. Hatch-Waxman Amendments, 21 U.S.C. §§ 355, 360cc; 35 U.S.C. § 271(e)(2).